#efta01192267
LightNews LightNews
epsteinweb.bsky.social
EFTA01192267.jpg
#epsteinweb #efta01192267
https://epsteinweb.org
Available in the iOS app store now!
https://apps.apple.com/us/app/epstein-web/id6758880661
EFTA01192266 | EFTA01192267 Methods: Forty cancer patients to be randomized to Citrus AntiFatigue powder (daily? BID?) versus placebo for eight weeks. Inclusion criteria: • Adult cancer survivors (>18 years) • All tumor types with the exception of patients with brain tumor or central nervous system metastasis to improve external validity • Patients actively receiving chemotherapy or radiation treatment for curative intent or have completed treatment within the last 12 months • Baseline CRF score of >5/10 (on an 11-point scale where 0 is "no fatigue" and 10 equal to "worst fatigue imaginable". Exclusion criteria: • Those who have previously used ginseng, glutamine, or caffeine or other agents for fatigue for 4 weeks prior to the start of the study are not eligible. • Change in chemotherapy or radiation therapy plans during the study period • Brain tumors or central nervous system metastasis • Anemia (hemoglobin <8.0 gm/dl), hypothyroidism, or other medical comorbidities that are felt to contribute to fatigue Outcome Measures: • Assessments to be carried out at baseline, 4 weeks, and 8 weeks. • Assessment tools would include: o FACIT-F o PROMIS Item Bank — Fatigue — Short Form o Common Terminology Criteria for Adverse Events (CTCAE) to evaluate for any toxicities related to Citrus AntiFatigue powder. EFTA01192267
May 13, 2026 at 12:30 AM